58 related articles for article (PubMed ID: 15505422)
1. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.
Aguirre D; Boya P; Bellet D; Faivre S; Troalen F; Benard J; Saulnier P; Hopkins-Donaldson S; Zangemeister-Wittke U; Kroemer G; Raymond E
Apoptosis; 2004 Nov; 9(6):797-805. PubMed ID: 15505422
[TBL] [Abstract][Full Text] [Related]
2. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
Zhu D; Huang J; Liu N; Li W; Yan L
Cell Death Dis; 2021 Jul; 12(8):730. PubMed ID: 34294689
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.
Saamarthy K; Ahlqvist K; Daams R; Balagunaseelan N; Rinaldo-Matthis A; Kazi JU; Sime W; Massoumi R
BMC Cancer; 2024 Jan; 24(1):103. PubMed ID: 38238702
[TBL] [Abstract][Full Text] [Related]
4. Loss of Mediator complex subunit 13 (MED13) promotes resistance to alkylation through cyclin D1 upregulation.
Roliński M; Montaldo NP; Aksu ME; Fordyce Martin SL; Brambilla A; Kunath N; Johansen J; Erlandsen SE; Liabbak NB; Rian K; Bjørås M; Sætrom P; van Loon B
Nucleic Acids Res; 2021 Feb; 49(3):1470-1484. PubMed ID: 33444446
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics profiling and chemoresistance mechanisms in ovarian cancer cell lines: Implications for targeting glutathione pathway.
Alarcon-Zapata P; Perez AJ; Toledo-Oñate K; Contreras H; Ormazabal V; Nova-Lamperti E; Aguayo CA; Salomon C; Zuniga FA
Life Sci; 2023 Nov; 333():122166. PubMed ID: 37827232
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin as a Potential Alternative Drug for Squamous Cell Gingiva Carcinoma (Ca9-22): A Focus on Cell Cycle, Apoptosis and Autophagy Genetic Profile.
Papadakos S; Issa H; Alamri A; Alamri A; Semlali A
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38276004
[TBL] [Abstract][Full Text] [Related]
7. Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
Mikhael S; Kurdi A; Khoueiry-Zgheib N; Tahtouh R; Nasr R; Hilal G
PLoS One; 2024; 19(3):e0298127. PubMed ID: 38489280
[TBL] [Abstract][Full Text] [Related]
8. The Role of CDK4/6 Inhibition in Breast Cancer.
Murphy CG; Dickler MN
Oncologist; 2015 May; 20(5):483-90. PubMed ID: 25876993
[TBL] [Abstract][Full Text] [Related]
9. Biological Screening of
Ahmad R; Alqathama A; Aldholmi M; Riaz M; Mukhtar MH; Aljishi F; Althomali E; Alamer MA; Alsulaiman M; Ayashy A; Alshowaiki M
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678504
[TBL] [Abstract][Full Text] [Related]
10. The multifaced role and therapeutic regulation of autophagy in ovarian cancer.
Nokhostin F; Azadehrah M; Azadehrah M
Clin Transl Oncol; 2023 May; 25(5):1207-1217. PubMed ID: 36534371
[TBL] [Abstract][Full Text] [Related]
11. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
13. LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer.
Wang F; Liang S; Liu X; Han L; Wang J; Du Q
Onco Targets Ther; 2018; 11():6383-6394. PubMed ID: 30323616
[TBL] [Abstract][Full Text] [Related]
14. Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
Faes S; Santoro T; Demartines N; Dormond O
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29104248
[TBL] [Abstract][Full Text] [Related]
15. Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel.
Yilmaz A; Alp E; Onen HI; Menevse S
Contemp Oncol (Pozn); 2016; 20(1):28-32. PubMed ID: 27095936
[TBL] [Abstract][Full Text] [Related]
16. Multiple gene aberrations and breast cancer: lessons from super-responders.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
[TBL] [Abstract][Full Text] [Related]
17. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Han B; Park D; Li R; Xie M; Owonikoko TK; Zhang G; Sica GL; Ding C; Zhou J; Magis AT; Chen ZG; Shin DM; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Cell; 2015 Jun; 27(6):852-63. PubMed ID: 26004684
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Wheler JJ; Moulder SL; Naing A; Janku F; Piha-Paul SA; Falchook GS; Zinner R; Tsimberidou AM; Fu S; Hong DS; Atkins JT; Yelensky R; Stephens PJ; Kurzrock R
Oncotarget; 2014 May; 5(10):3029-38. PubMed ID: 24912489
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
Pavlidou A; Vlahos NF
ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
[TBL] [Abstract][Full Text] [Related]
20. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Matter MS; Decaens T; Andersen JB; Thorgeirsson SS
J Hepatol; 2014 Apr; 60(4):855-65. PubMed ID: 24308993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
